Cecilio S. V.
- Country
- Spain
- Department
- Gastroenterologist
Research Overview
- Efficacy and Safety Evaluation of Barzolvolimab in Adults with Active Eosinophilic Esophagitis: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety of Tezepelumab in Eosinophilic Esophagitis: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
- Non-Inferiority Phase III Trial of Budesonide Orodispersible Tablets for Inducing Histological Remission in Adult Eosinophilic Esophagitis
Data & Insights
Has run more than one trial at 21 of 85 partner sites.
Specializations
Inflammatory Disorders
Specializes in investigating therapeutic approaches for eosinophilic esophagitis (EoE), a rare chronic inflammatory condition affecting the esophagus. The investigator's work focuses on understanding immune-mediated responses triggered by food and aeroallergens.
- Esophageal inflammation management
- Immune response modulation
- Chronic inflammatory disorders
Particular emphasis on evaluating novel therapeutic interventions for inflammatory esophageal conditions.
Therapeutic Innovation
Conducts research on various innovative treatments including biologics and targeted therapies such as tezepelumab, solrikitug, and barzolvolimab for esophageal disorders.
- Novel therapeutic compounds
- Biological response modifiers
- Treatment optimization strategies
Active involvement in evaluating both established and emerging therapeutic approaches.
Clinical Outcomes
Focuses on assessing therapeutic efficacy through histologic responses and symptom improvement in patients with esophageal conditions.
- Histological assessment
- Symptom evaluation
- Long-term treatment outcomes
Specialized interest in measuring both clinical and histological parameters of treatment success.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.